← Back to Clinical Trials
Recruiting NCT01719055

NCT01719055 RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT01719055
Status Recruiting
Phase
Sponsor Boston Scientific Corporation
Condition Pain
Study Type OBSERVATIONAL
Enrollment 4,800 participants
Start Date 2012-11-19
Primary Completion 2035-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
neurostimulation system

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 4,800 participants in total. It began in 2012-11-19 with a primary completion date of 2035-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To compile characteristics of real-world clinical outcomes for Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice, when used according to the applicable Instructions for Use \- and - To evaluate the economic value and technical performance of Boston Scientific commercially approved neurostimulation systems for pain in routine clinical practice

Eligibility Criteria

Key Inclusion Criteria: * Study candidate is scheduled to be trialed, on-label, with a commercially approved Boston Scientific neurostimulation system for pain, per local directions for use * Signed a valid, IRB/EC-approved informed consent form * 18 years of age or older Key Exclusion Criteria: * Contraindicated for Boston Scientific neurostimulation system * Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments

Contact & Investigator

Central Contact

Thanh Hoang, MS

✉ BSNClinicalTrials@bsci.com

📞 855-213-9890

Principal Investigator

Natalie Bloom Lyons

STUDY DIRECTOR

Boston Scientific Corporation

Frequently Asked Questions

Who can join the NCT01719055 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT01719055 currently recruiting?

Yes, NCT01719055 is actively recruiting participants. Contact the research team at BSNClinicalTrials@bsci.com for enrollment information.

Where is the NCT01719055 trial being conducted?

This trial is being conducted at Phoenix, United States, Phoenix, United States, Tucson, United States, Campbell, United States and 11 additional locations.

Who is sponsoring the NCT01719055 clinical trial?

NCT01719055 is sponsored by Boston Scientific Corporation. The principal investigator is Natalie Bloom Lyons at Boston Scientific Corporation. The trial plans to enroll 4,800 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology